Therapeutic microbiota for the treatment and/or prevention of food allergy

Abstract

Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy. In certain embodiments, the consortia comprise certain members of the taxa Clostridiales and/or Bacteroidetes.

1 .- 159 . (canceled) 
     
     
         160 . A pharmaceutical composition, comprising:
 a purified mixture of live and isolated bacteria, wherein the purified mixture of live and isolated bacteria comprises:  Bacteroides fragilis, Bacteroides ovatus , and  Parabacteroides distasonis ; and   (ii) a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated for oral administration.   
     
     
         161 . The pharmaceutical composition of  claim 161 , wherein the pharmaceutical composition is formulated as a suspension, gel, or fluid-gel. 
     
     
         162 . The pharmaceutical composition of  claim 162 , wherein the suspension is an aqueous or oily suspension. 
     
     
         163 . The pharmaceutical composition of  claim 160 , wherein the pharmaceutical composition is formulated as a capsule, a reconstituted lyophilisate, a food item, or a liquid. 
     
     
         164 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria further comprises at least one species of  Clostridium.    
     
     
         165 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria comprises up to 11 strains of bacteria. 
     
     
         166 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria comprises from 4 to 30 strains of bacteria. 
     
     
         167 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria comprises strains present in substantially equal biomass. 
     
     
         168 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria comprises strains present in a total amount of at least 1×10 5  CFUs. 
     
     
         169 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria comprises strains present in a total amount of at least 1×10 8  CFUs. 
     
     
         170 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria comprises strains present in an amount of at least 1×10 8  CFUs/ml. 
     
     
         171 . The pharmaceutical composition of  claim 160 , wherein the purified mixture of live and isolated bacteria does not comprise  Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Bilophila wadsworthia, Alistipes onderdonkii, Desulfovibrio  species,  Lactobacillus johnsonii , or  Parasutterella excrementihominis.    
     
     
         172 . A method comprising orally administering to a subject having an inflammatory disorder a pharmaceutical composition comprising:
 (i) a purified mixture of live and isolated bacteria for treatment of an inflammatory disorder in an individual in need thereof, wherein the purified mixture of live and isolated bacteria comprises:  Bacteroides fragilis, Bacteroides ovatus , and  Parabacteroides distasonis; and      (ii) a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated for oral administration.   
     
     
         173 . The method of  claim 172 , wherein the pharmaceutical composition is formulated as a suspension, gel, or fluid-gel. 
     
     
         174 . The method of  claim 172 , wherein the suspension is an aqueous or oily suspension. 
     
     
         175 . The method of  claim 172 , wherein the purified mixture of live and isolated bacteria comprises up to 11 strains of bacteria. 
     
     
         176 . The method of  claim 172 , wherein the purified mixture of live and isolated bacteria comprises from 4 to 30 strains of bacteria. 
     
     
         177 . The method of  claim 172 , wherein the purified mixture of live and isolated bacteria comprises strains present in substantially equal biomass. 
     
     
         178 . The method of  claim 172 , wherein the purified mixture of live and isolated bacteria comprises strains present in a total amount of at least 1×10 5  CFUs. 
     
     
         179 . The method of  claim 172 , wherein the inflammatory disorder is a food allergy. 
     
     
         180 . The method of  claim 179 , wherein the food allergy is an allergy to soy, wheat, eggs, dairy, peanuts, tree nuts, shellfish, fish, mushrooms, or stone fruits.